ArticleDrug, healthcare and patient safety2015

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States.

Michele Jara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.